Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials

被引：0
|
作者：
Siegel, D. S. [1 ]
Martin, T. [2 ]
Nooka, A. [3 ]
Harvey, R. D. [3 ]
Vij, R. [4 ]
Niesvizky, R. [5 ]
Badros, A. Z. [6 ]
Jagannath, S. [7 ]
McCulloch, L. [8 ]
Rajangam, K. [8 ]
Lonial, S. [3 ]
机构：
[1] John Theurer Canc Ctr, Hackensack, NJ USA
[2] UCSF, San Francisco, CA USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[7] Mt Sinai Med Ctr, New York, NY 10029 USA
[8] Onyx Pharmaceut Inc, San Francisco, CA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
42
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
    Siegel, D.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lenial, S.
    [J]. ONKOLOGIE, 2013, 36 : 39 - 40
  • [2] HEMATOLOGIC SAFETY PROFILE OF SINGLE-AGENT CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA FROM FOUR PHASE 2 STUDIES
    Nooka, A.
    [J]. HAEMATOLOGICA, 2012, 97 : 601 - 601
  • [3] Cardiac and pulmonary safety profile of patients with relapsed and/or refractory multiple myeloma from four phase 2 studies of single-agent carfilzomib
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 : 19 - 19
  • [4] Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    [J]. BLOOD, 2012, 120 (21)
  • [5] Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
    Nooka, Ajay K.
    Badros, Ashraf Z.
    Patel, Priti
    McCulloch, Leanne
    Lonial, Sagar
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials
    Wang, Luhua
    Siegel, David S.
    Jakubowiak, Andrzej J.
    Wong, Alvin F.
    Dixon, Sandra
    Renau, Thomas E.
    Vij, Ravi
    [J]. BLOOD, 2011, 118 (21) : 1698 - 1698
  • [7] From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma
    Siegel, David S.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (06) : 354 - 365
  • [8] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    [J]. BLOOD, 2009, 114 (04) : 772 - 778
  • [9] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [10] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
12345